The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a critical member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is the first-generation EGFR-TKIs, the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line age...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Zhou, Jian-Guo, Tian, Xu, Cheng, Long, Zhou, Quan, Liu, Yuan, Zhang, Yu, Bai, Yu-ju, Ma, Hu
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2015
Teme:
5700
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4616758/
https://ncbi.nlm.nih.gov/pubmed/26448029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000001719
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki